Rex Geveden Sells 10,000 Shares of BWX Technologies (NYSE:BWXT) Stock

BWX Technologies, Inc. (NYSE:BWXT) CEO Rex Geveden sold 10,000 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $203.26, for a total transaction of $2,032,600.00. Following the completion of the transaction, the chief executive officer owned 177,594 shares in the company, valued at approximately $36,097,756.44. The trade was a 5.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BWX Technologies Trading Up 1.7%

Shares of BWXT stock opened at $200.31 on Friday. BWX Technologies, Inc. has a 12-month low of $84.21 and a 12-month high of $220.57. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 1.21. The company has a 50 day moving average of $192.65 and a 200-day moving average of $185.00. The firm has a market cap of $18.31 billion, a P/E ratio of 60.15, a PEG ratio of 3.22 and a beta of 0.84.

Hedge Funds Weigh In On BWX Technologies

A number of hedge funds have recently modified their holdings of the company. Aventura Private Wealth LLC bought a new stake in shares of BWX Technologies in the fourth quarter worth about $29,000. Strategic Advocates LLC bought a new stake in shares of BWX Technologies in the 3rd quarter worth approximately $32,000. Creative Financial Designs Inc. ADV grew its position in shares of BWX Technologies by 250.0% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 175 shares of the technology company’s stock worth $25,000 after buying an additional 125 shares during the last quarter. Global Trust Asset Management LLC purchased a new position in shares of BWX Technologies during the third quarter valued at approximately $32,000. Finally, Strategic Investment Solutions Inc. IL raised its holdings in shares of BWX Technologies by 300.0% during the third quarter. Strategic Investment Solutions Inc. IL now owns 200 shares of the technology company’s stock valued at $37,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.

Analysts Set New Price Targets

BWXT has been the topic of a number of research reports. Bank of America raised their price objective on BWX Technologies from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Truist Financial set a $205.00 price target on shares of BWX Technologies in a research note on Friday, January 9th. Weiss Ratings cut shares of BWX Technologies from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Zacks Research raised shares of BWX Technologies from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, BTIG Research boosted their price target on shares of BWX Technologies from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, BWX Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $199.20.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.